Calcipotriene/betamethasone dipropionate: a new topical ointment for psoriasis

Author: Guenther, Lyn C

Source: Expert Review of Dermatology, Volume 1, Number 6, December 2006 , pp. 791-797(7)

Publisher: Expert Reviews

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Topical steroids and calcipotriene are the mainstay of treatment for mild-to-moderate psoriasis. They are used as monotherapy or in combination in an a.m./p.m. regimen owing to drug incompatibility. Recently, the US FDA approved a once-daily stable two-compound ointment containing calcipotriene and betamethasone dipropionate (Taclonex®). This product has been marketed in other countries under the names Dovobet® and Daivobet®. It is convenient with a faster speed of onset and greater efficacy than its individual ingredients or tacalcitol. After 4 weeks of therapy, the psoriasis area and severity index is reduced by approximately 70% and half of the patients have absent or very mild disease. Furthermore, more than half of the patients reach PASI-75 after 4 weeks of treatment. The calcipotriene/betamethasone dipropionate ointment is well tolerated with a safety profile similar to betamethasone dipropionate. It is associated with 50 and 75% fewer cutaneous adverse events than calcipotriene and tacalcitol, respectively.

Keywords: betamethasone dipropionate; calcipotriene; calcipotriol; fixed combination; psoriasis

Document Type: Research article

DOI: 10.1586/17469872.1.6.791

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A